What's Happening?
BeOne Medicines has announced the publication of data from its Phase 3 HERIZON-GEA-01 trial in The New England Journal of Medicine, with findings also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated the efficacy
and safety of ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), compared to the standard treatment of trastuzumab plus chemotherapy for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). The study involved 914 patients across 30 countries. Results showed a statistically significant improvement in overall survival, with the ZIIHERA plus TEVIMBRA combination achieving a median overall survival of 26.4 months, compared to 19.2 months for the control group. The trial also demonstrated improved progression-free survival and duration of response.
Why It's Important?
The findings from the HERIZON-GEA-01 trial are significant as they offer a potential new treatment option for patients with HER2-positive gastroesophageal adenocarcinoma, a condition with high morbidity and mortality. The combination of ZIIHERA and TEVIMBRA could become a new standard of care, providing a longer survival benefit even in patients with low PD-L1 expression. This development is crucial as it addresses a critical unmet need in cancer treatment, potentially improving outcomes for a significant number of patients worldwide. The trial's success also underscores the importance of innovative therapeutic combinations in oncology.
What's Next?
The U.S. FDA has accepted a supplemental Biologics License Application for TEVIMBRA and granted it priority review, indicating a potential expedited path to approval. BeOne Medicines plans to work with regulatory authorities in various markets to expedite submissions, aiming to make this treatment available to patients as soon as possible. The company holds rights to ZIIHERA in Asia, Australia, and New Zealand, and intends to pursue regulatory approvals in these regions. The ongoing regulatory processes will be closely watched by stakeholders in the oncology community.
